Aplenzin (Bupropion HBr) Patent Expiration, LOE Window & CMS Spending

Aplenzin (Bupropion HBr) by Bausch Health: FDA Orange Book LOE 2026-06-27, 32 AB generics, $40.2M 2024 CMS Part D & Medicaid spend, and 15 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBausch Health
FDA Application & PathwayN022108 (NDA)
Exclusivity / Cliff HorizonImmediate Cliff (2025-2027)
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity Date2026-06-27
Orange Book Patents (*PED Extensions)8 patents (0 *PED)
Active AB-Rated Generic Competitors32
2024 CMS Total Public Spend$40.2M
2024 Medicare Part D Spend$23.5M
2024 Medicaid Spend$16.7M
Reported Wholesale Price Change (CA SB 17)15 WAC filings (max 45.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bausch Health / Bausch + Lomb across sibling Meru public-data platforms.